It is crucial to identify those patients who have a realistic chance to taper medications. However, there is no consensus on the relapse rate decrease that would allow discontinuation of DMTs. I would suggest classifying patients into three groups: the "early remission" group, when remission was achieved within 5 years after baseline; the "intermediate remission" group, when remission was achieved between 5 and 10 years after baseline; and the "late remission" group, when remission was obtained after 10 years. Remission would be defined as sustained absence of clinical relapses or new lesions on imaging for the entire follow-up period.
Treatment cessation in stable patients should be optional and based on an unbiased discussion of the pros and cons. In the lack of scientific evidence, discontinuation of DMTs in patients with NMOSD is a difficult decision based on incomplete data as it is yet unknown whether this disease outcome is modifiable with current medications. De-escalation therapy would be an alternative in patients who have been stable on rituximab for several years, with a dosing interval of 12 months instead of 24 months doses, or with a switch to azathioprine or mycophenolate mofetil. Large prospective randomized trials in a larger population of patients are needed to provide guidelines on the optimal approach.
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The author(s) received no financial support for the research, authorship, and/or publication of this article. The possibility of an exit plan for discontinuing therapy is a frequently posed question in the clinic, but one of the least studied aspects of medical management. Clinical trials focus on the benefits of therapeutic intervention at the moment when disease is most active. In the case of multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), clinical trial inclusion criteria routinely require evidence of a relapse or gadolinium-enhancing lesions within the past 1-2 years. Yet particularly for chronic inflammatory disorders, the propensity for new activity may wane over time, while the potential for adverse events on immunotherapy is thought to increase as patients age.
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In MS, investigators are beginning to address how to safely stop therapy. Disease-modifying therapies (DMT) are known to be less effective in older patients with relapsing-remitting multiple sclerosis (RRMS) 1 and none of the currently approved therapies has demonstrated efficacy in secondary progressive multiple sclerosis (SPMS). In an ongoing randomized controlled trial in the United States, DISCOMS (see ClinicalTrials.gov), patients may be randomized to DMT discontinuation if they are ⩾55 years and do not have evidence of a relapse or new magnetic resonance imaging (MRI) lesion within the preceding 5 years.
NMOSD, however, is a demyelinating disease with a distinct clinical course and pathophysiology compared to MS, and at this time, we do not have evidence that DMT can be safely stopped. Identification of the pathologic aquaporin-4 antibody (AQP4 IgG) has led to increased recognition of cases; the cellbased AQP4 IgG assay is both highly sensitive and specific. 2 AQP4 is a key protein in the water channel of astrocytes, with the presence of the antibody leading to widespread astrocyte loss. NMOSD has considerable immunopathologic overlap with myasthenia gravis, another inflammatory channelopathy entailing complement system activation, and often striking and requiring treatment into old age.
Previously, DMT approaches for NMOSD have been based on retrospective case series. Commonly used agents include rituximab, azathioprine, and mycophenolate. While these therapies are generally well tolerated, they do pose an increased risk of infection, and the latter two cause considerable gastrointestinal side effects in some patients. Concerns have been raised about whether all three therapies may lead to a slight increase in rates of malignancy.
However, these risks are small compared to the risk of a new disabling attack. Age does not appear to significantly diminish the risk of relapse in NMOSD, as it does in MS. NMOSD commonly presents across the full range of age, with many presenting at ages ⩾55 years and reported cases occurring in patients into their eighties. 3, 4 Even with earlier NMOSD onset, relapses often continue in those ⩾55 years. 4 Moreover, the consequence of relapse in NMOSD is routinely much graver than in MS. Disability, including vision loss, paresis, and gait impairment, occurs largely from relapses themselves. Patients often recover poorly from individual attacks despite intervention with highdose corticosteroids and/or plasma exchange. In a large retrospective study of 185 NMOSD subjects with a total of 871 attacks, the first course of therapy resulted in complete remission in only 19.1% of relapses. 5 With MS therapy, a trial of DMT withdrawal may be attempted, with the calculated gamble that if a relapse occurs, the patient will likely recover well and therapy can be re-instituted. In NMOSD, this kind of gamble can lead to irrevocable disability particularly in older patients. Predictors of complete remission from an NMOSD relapse include isolated unilateral optic neuritis, younger age, recovery from the previous attack, and first-line plasma exchange or immunotherapy (vs highdose corticosteroids alone), 5 but overall predictive power remains weak.
A subset of seronegative NMOSD patients is now known to be seropositive for myelin oligodendrocyte glycoprotein antibody (MOG IgG); several studies have established a greater likelihood of monophasic disease in MOG+ cases. 6, 7 These patients should be considered separately as they have a unique disease process with milder relapses and without evidence of astrocytopathy. While older NMO natural history studies reported that a share of NMOSD cases remained monophasic, 8 a significant number of these were likely attributable to MOG+ disease. 6, 7 There is conflicting evidence around whether so-called "double negative" patients, negative for both AQP4 IgG and MOG IgG, may have a milder disease course than AQP4+ patients, and further study of this group is necessary.
On the other hand, even with AQP4+ disease relapse rate varies considerably and there may be long relapse-free intervals. 8 Cases of spontaneous remission of approximately 20 years have been reported in AQP4+ NMOSD subjects off of therapy, but are extremely rare. 9 In some cases of prolonged remission, patients eventually relapsed again, including permanently disabling attacks. 9 Thus, in almost all cases of NMOSD, current evidence suggests that the potential benefits outweigh the risks of DMT.
How can we determine in the future whether and when DMT can be safely stopped in NMOSD? Large, multi-national prospective longitudinal studies are required to identify clinical features and biomarkers consistently associated with prognosis and disease course. While in MS, suggested criteria for discontinuation of therapy have included age and absence of disease activity within 5 years, there may be other clinical criteria more relevant for NMOSD management, such as extent of recovery from past relapses and longer relapse-free intervals. Ideally, we should incorporate biomarkers to measure inflammatory activity prior to discontinuing therapy and afterward to assess for resurgence. Biomarkers under investigation include serum and cerebrospinal fluid (CSF) glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL). 10 Serum NfL has shown potential for predicting new relapses and gadoliniumenhancing lesions in RRMS, but GFAP has been studied more extensively in NMOSD subjects to date. There is evidence that CSF and serum GFAP levels correlate well, and there is a strong association between GFAP levels and NMOSD relapse, although it is not known whether GFAP levels may rise in advance of relapse. 10 Other candidate biomarkers include CXCXL12, a B-cell chemokine, and interleukin (IL)-6 levels, although the latter may become less relevant if the IL-6 receptor blocker, satralizumab, becomes a common add-on therapy.
While current evidence suggests that DMT must be continued long term, in the future, prospective clinical studies and validated biomarkers will guide personalized treatment plans in NMOSD. With several new potential NMOSD treatments on the horizon, the exit plan may be re-defined in terms of de-escalation strategies to allow for less intensive or costly therapeutic regimens, or transition from combination therapy to monotherapy. The emergence of the first generation of disease-modifying therapies (DMTs) for multiple sclerosis (MS) and clinically isolated syndrome sparked debate about when to start treatment. Now, more than two decades later, some individuals with a lengthy history of relapsing MS have experienced the good fortune of an extended and ongoing period (5+ years) of no evidence of disease activity (NEDA). Most importantly,
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